Refine
Has Fulltext
- yes (175)
Is part of the Bibliography
- yes (175)
Year of publication
Document Type
- Journal article (175) (remove)
Language
- English (175)
Keywords
- PET (22)
- positron emission tomography (21)
- prostate cancer (16)
- Positronen-Emissions-Tomografie (15)
- theranostics (14)
- CXCR4 (13)
- PET/CT (12)
- PRRT (10)
- multiple myeloma (10)
- PSMA (9)
- dosimetry (8)
- neuroendocrine tumor (8)
- radioligand therapy (8)
- SPECT (7)
- molecular imaging (6)
- 53BP1 (5)
- chemokine receptor (5)
- FDG (4)
- NET (4)
- Parkinson’s disease (4)
- SSTR (4)
- biokinetics (4)
- inflammation (4)
- lymphoma (4)
- medicine (4)
- norepinephrine transporter (4)
- radiotherapy (4)
- somatostatin receptor (4)
- sympathetic nervous system (4)
- γ-H2AX (4)
- 18F-FDG (3)
- 18F-FDG PET/CT (3)
- MRI (3)
- RADS (3)
- adrenocortical carcinoma (3)
- dopamine (3)
- imaging (3)
- machine learning (3)
- peptide receptor radionuclide therapy (3)
- prostate-specific membrane antigen (3)
- prostate-specific membrane antigen (PSMA) (3)
- radioiodine therapy (3)
- radionuclide therapy (3)
- salvage radiotherapy (3)
- 123I-mIBG (2)
- 123I-metaiodobenzylguanidine (2)
- 177Lu (2)
- 18F-FDS (2)
- 18F-LMI1195 (2)
- C-X-C motif chemokine receptor 4 (2)
- DNA damage (2)
- DNA repair (2)
- DOTATOC (2)
- FDG PET/CT (2)
- MAG3 (2)
- MIBG (2)
- Oncology (2)
- PSMA I&T (2)
- PSMA-RADS (2)
- Parkinson's disease (2)
- Positron emission tomography (2)
- Prostate Cancer (2)
- Radionuclide Therapy (2)
- SPECT/CT (2)
- SUV (2)
- Thyroid cancer (2)
- [68Ga]PentixaFor (2)
- antidepressant (2)
- biodosimetry (2)
- biomarkers (2)
- bone disease (2)
- brain (2)
- cancer (2)
- cancer treatment (2)
- cardiac (2)
- cardiac innervation imaging (2)
- cardiac nerve (2)
- children (2)
- diabetes (2)
- endoradiotherapy (2)
- fibroblast activation protein (2)
- glioblastoma multiforme (2)
- guidelines (2)
- heart failure (2)
- immunohistochemistry (2)
- in vivo imaging (2)
- involvement (2)
- isotopes (2)
- kidney (2)
- magnetic resonance imaging (2)
- management (2)
- medullary thyroid carcinoma (2)
- meningioma (2)
- metabolism (2)
- molecular medicine (2)
- myocardial sympathetic innervation imaging (2)
- nuclear medicine (2)
- personalized medicine (2)
- personalized treatment (2)
- positron emission tomography/computed tomography (2)
- precision medicine (2)
- prognosis (2)
- quantitative SPECT/CT (2)
- radial (2)
- radioiodine (2)
- radiopharmaceuticals (2)
- relapse (2)
- repair (2)
- reporting and data system (2)
- risk (2)
- sarcoidosis (2)
- somatostatin receptor (SSTR) (2)
- survival (2)
- thyroid cancer (2)
- tyrosine kinase inhibitor (2)
- vandetanib (2)
- 11C-HED (1)
- 11C-Hydroxyephedrine (1)
- 11C-Methionine PET/CT (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 131I (1)
- 133Ba (1)
- 177Lu SPECT/CT imaging (1)
- 18-F-fluorothymidine uptake (1)
- 18F-DCFPL (1)
- 18F-DCFPyL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 1st International Workshop (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 2015 (1)
- 223Ra (1)
- 224Ra (1)
- 3D printing (1)
- 5-Fluorouracil (1)
- 5IA-SPECT (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- 99mTc-DTPA (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- Alzheimer’s disease (1)
- American Thyroid Association (1)
- Antibodies (1)
- Antidepressants (1)
- Arginine (1)
- B-cell lymphoma (1)
- BON-1 (1)
- BRAF mutation (1)
- BRAF(V600E) mutation (1)
- BSS directive (1)
- Barium-133 (1)
- Biokinetics (1)
- C-11-methionine pet (1)
- CD38 (1)
- CNS cancer (1)
- COVID-19 (1)
- CTCAE (1)
- CTNNB1 (1)
- CXCR4-targeting (1)
- CXCR4/SDF-1 (1)
- CXCR7 (1)
- CYP11B enzymes (1)
- Capicua transcriptional repressor (1)
- Carbon-11 (1)
- Cardiology (1)
- Cardiovascular diseases (1)
- Central venous access (1)
- Chernobyl (1)
- Conjugate arc therapy (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- DCGAN (1)
- DLBCL (1)
- DNA Breaks (1)
- DNA Damage Repair (1)
- DNA double-strand breaks (1)
- DOPA-responsive-dystonia (1)
- DOTA-EB-TATE (1)
- DSB damage (1)
- DSB focus substructure (1)
- DWI (1)
- DYT1 (1)
- DaTscan (1)
- Deep learning (1)
- Denoising (1)
- Diagnostic radiopharmaceuticals (1)
- Dosimetry (1)
- Drug resistance (1)
- Dystonia (1)
- E-cadherin (1)
- EANM (1)
- EANM dosage card (1)
- ECG (1)
- Effective dose (1)
- Extramedullary disease (1)
- Extraocular eye muscles (1)
- F-18-FDG PET (1)
- FAP (1)
- FAPI PET/CT (1)
- FDG-PET (1)
- FDG-PET/CT (1)
- FDG-PET/MRI (1)
- FLT-PET (1)
- FV45 (1)
- Fabry Disease (FD) (1)
- GAN (1)
- GCA (1)
- GCH1 (1)
- GI (1)
- Ga-68 (1)
- Ganglia (1)
- Gastrointestinal (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- German population (1)
- Gleason score (1)
- Glomerular filtration (1)
- HFmrEF (1)
- HMDP hydroxymethylene diphosphonate (1)
- Hamburg (1)
- Heart failure (1)
- Hickman catheter (1)
- Highlights Lecture (1)
- Hodgkin-lymphoma (1)
- Hyperkalaemia (1)
- IBA-1 (1)
- ICD (1)
- Imaging pitfalls (1)
- JR11 (1)
- Journal of Nuclear Cardiology (1)
- KWIC (1)
- Lu-177 (1)
- Lutetium (1)
- Lysine (1)
- MDD (1)
- MIBG scintigraphy (1)
- MOR202 (1)
- MPI (1)
- MS-18 (1)
- Magnetresonanztomografie (1)
- Matlab (1)
- Medullärer Schilddrüsenkrebs (1)
- Merkel cell carcinoma (1)
- Metastases (1)
- Molecular Imaging (1)
- Molecular imaging (1)
- Monte Carlo (1)
- Multiple myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- Myocardial perfusion (1)
- Myocardial-perfusion SPECT (1)
- Myokarditis (1)
- NEC (1)
- NR3C1 (1)
- NVP-BGT226 (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Neurosciences (1)
- Nierenfunktionsstörung (1)
- OPS201 (1)
- OXPHOS (1)
- P-glycoprotein expression (1)
- PET/MR systems (1)
- PMR (1)
- PSA (1)
- PSA response (1)
- PSMA PET/CT (1)
- PSMA-617 (1)
- PSMA-PET (1)
- PSMA-TV (1)
- PSMA‐617 (1)
- Parkinson disease (1)
- Parkinsonism (1)
- Parkionson's disease (1)
- Pediatric malignancy (1)
- Pentixafor (1)
- Phase-II (1)
- Physics and instrumentation (1)
- Pitfall (1)
- Port (1)
- Positron Emission Tomography (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Preclinical evaluation (1)
- Primary hyperparathyroidism (pHPT) (1)
- Prostata (1)
- Prostate-cancer (1)
- QGP-1 (1)
- RLT (1)
- ROS (1)
- Ra-224 (1)
- Radiofluorine (1)
- Radioiodine Therapy (1)
- Radionuclide therapy (1)
- Radiopharmacy (1)
- Radiotracer (1)
- Radium (1)
- Raman micro-spectroscopy (1)
- Rhabdomyosarcoma (1)
- SAH (1)
- SARS-CoV-2 (1)
- SPECT Scanner (1)
- SSTR-PET (1)
- SSTR-RADS (1)
- Simvastatin (1)
- Single Molecule Localization Microscopy (SMLM) (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- Somatostatin receptor expression (1)
- Stammzelle (1)
- Standardisierung (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- T1rho (1)
- T1ρ (1)
- TBI (1)
- TKI (1)
- TSPO (1)
- TT\(_{1rho}\) mapping (1)
- T\(_{1P}\) dispersion (1)
- T\(_{1P}\) mapping (1)
- Targeted therapy (1)
- Technetium Tc 99m Sestamibi Rats (1)
- Thrombosis (1)
- Tracer (1)
- USP28 (1)
- USP8 (1)
- Virchow Node (1)
- WB-DW-MRI (1)
- Waldeyer’s tonsillar ring (1)
- Wnt (1)
- ZDF rats (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [177Lu]-DOTATATE/-DOTATOC (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [68Ga] (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [99mTc]-Sestamibi scan (1)
- [\(^{223}\)Ra]RaCl\(_{2}\) (1)
- [\(^{68}\)Ga] Pentixafor (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{177}\)Lu (1)
- \(^{177}\)Lu-OPS201 (1)
- \(^{18}\)F (1)
- \(^{18}\)F-DCFPyL PET/CT (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- \(^{68}\)Ga-Pentixafor (1)
- \(^{99m}\)Tc-MAG3 (1)
- abdominal lymph node metastases (1)
- absorbed dose (1)
- absorbed dose to the blood (1)
- accuracy (1)
- acute myeloid leukemia (1)
- acute renal failure (1)
- adenocarcinoma of the lung (1)
- adrenal incidentaloma (1)
- adrenocortical (1)
- adsorption (1)
- advanced stages (1)
- ageing (1)
- agreement (1)
- alpha particles (1)
- alpha-emitters (1)
- amino acids (1)
- amyloid-β (Aβ) (1)
- analysis (1)
- androgen deprivation therapy (1)
- angiogenesis (1)
- angiotensin II type 1 receptor (1)
- antagonist (1)
- anthropometric measurements (1)
- areas (1)
- arrhythmia (1)
- artificial intelligence (1)
- association (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- autoimmune thyroiditis (1)
- autologous transplantation (1)
- autoradiography (1)
- basal ganglia (1)
- base of support (1)
- benzylguanidine (1)
- beta oscillations (1)
- beta-catenin (1)
- biological dosimetry (1)
- biomarker (1)
- biosynthesis (1)
- blood (1)
- blood flow (1)
- bone marrow cells (1)
- bone-marrow (1)
- bone-targeting radiopharmaceuticals (1)
- brain metabolic alterations (1)
- brain tumors (1)
- breast cancer (1)
- buparlisib (1)
- butyrylcholinesterase (1)
- c-MYC (1)
- calcitonin (1)
- calibration (1)
- cancer associated fibroblasts (1)
- cancer of unknown primary (CUP) (1)
- cancer-associated fibroblast (1)
- carbamate (1)
- carboxylation (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cardiomyocytes (1)
- cardioprotective potential (1)
- cardiovascular diseases (1)
- caudate nucleus (1)
- cell biology (1)
- cell staining (1)
- cells (1)
- cerebral gliomas (1)
- chemokine receptor-4 (1)
- childhood and adolescence (1)
- cholinergic activity (1)
- chromatin mobility (1)
- clinical diagnosis (1)
- coefficient (1)
- cognitive decline (1)
- coherence analysis (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- collagens (1)
- collimator (1)
- combination (1)
- comparability (1)
- comparison exercise (1)
- complex DNA damage (1)
- computational biology and bioinformatics (1)
- contractility (1)
- contrast agent (1)
- coronary artery disease (1)
- correction (1)
- criteria (1)
- damage (1)
- daratumumab (1)
- data analysis (1)
- delineation (1)
- dementia (1)
- depression (1)
- detection rate (1)
- diabetic cardiomyopathy (1)
- diagnostic medical radiation exposure (1)
- diagnostics (1)
- differentiated thyroid cancer (1)
- differentiated thyroid carcinoma (1)
- diffuse (1)
- diffusion weighted MRI (1)
- diffusion weighted mri (1)
- dilated cardiomyopathy with ataxia (1)
- disease (1)
- dissection (1)
- distant metastases (1)
- dopamine acetylcholine (1)
- dopamine transporter (DAT) (1)
- dose response (1)
- double-stranded (1)
- drug discovery (1)
- early response (1)
- editorial (1)
- ejection fraction (1)
- endocrinology (1)
- enzyme kinetics (1)
- epidemiology (1)
- esophagogastric junction (1)
- evans blue (1)
- exome sequencing (1)
- experience (1)
- exposure (1)
- extracellular matrix (1)
- extramedullary hematopoiesis (1)
- fatty acid (1)
- flare phenomenon (1)
- fluorine-18 (1)
- focal (1)
- focused surgical approach (1)
- folinic acid (1)
- follicular lymphoma (1)
- follow-up (1)
- free‐breathing (1)
- gait initiation (1)
- gamma rays (1)
- gefitinib (1)
- gemcitabine (1)
- genetics (1)
- giant cell arteritis (1)
- glioblastoma (1)
- glioma (1)
- glomerular filtration rate (1)
- glucocorticoid excess (1)
- harmonization of SPECT/CT imaging (1)
- head and neck cancer (1)
- health care (1)
- healthy volunteers (1)
- heart (1)
- heart failure with mid-range ejection fraction (1)
- heart-to-mediastinum ratio (1)
- hematotoxicity (1)
- heptacellular carcinoma (1)
- hiPSC-CM (1)
- high LET irradiation (1)
- high risk (1)
- histone H2AX (1)
- humans (1)
- hypercortisolism (1)
- hyperkalemia (1)
- hypothyroidism (1)
- imaging proliferation (1)
- imaging techniques (1)
- immune check inhibitor (1)
- immune infiltration (1)
- immunostaining (1)
- improves (1)
- in vivo formation (1)
- in-vivo (1)
- induced pluripotent stem cells (1)
- inhibition (1)
- initial experience (1)
- international multicenter comparison exercise (1)
- intraindividual comparison (1)
- iodine contrast (1)
- iodine nutrition (1)
- iodine-131 (1)
- irinotecan (1)
- irradiation (1)
- isotopic labelling (1)
- kidney function (1)
- kinase inhibitor (1)
- late response (1)
- left-ventricular function (1)
- lesions (1)
- leukocytes (1)
- levodopa-induced dyskinesia (1)
- linear conversion (1)
- locally advanced disease (1)
- long-term complications (1)
- long-term outcome (1)
- lung (1)
- lung and intrathoracic tumors (1)
- lung cancer (1)
- lutetium-177 (1)
- mRNA (1)
- macrophages (1)
- macroscopic recurrence (1)
- major depressive disorder (1)
- malignancies (1)
- malignant lymphoma (1)
- mammalian target of rapamycin (1)
- mapping (1)
- matched pair (1)
- mechanisms retention (1)
- medium-sized animals (1)
- medullary thyroid cancer (1)
- metabolic tumor volume (MTV) (1)
- metabolic tumour volume (MTV) (1)
- metastasis-directed therapy (1)
- methionine (1)
- methionine pet (1)
- methylation (1)
- methylphenidate (1)
- miRNA (1)
- mice (1)
- microenvironment (1)
- microglial cells (1)
- mitochondria (1)
- molecular biology (1)
- molecular diagnostics (1)
- molecular radiotherapy (1)
- molecular radiotherapy (MRT) (1)
- motor control (1)
- mouse (1)
- movement disorders (1)
- multi-centre (1)
- multiple system atrophy (1)
- multivariate data analysis (1)
- myocardial nerve (1)
- myocardial perfusion imaging (1)
- myocarditis (1)
- nab-paclitaxel (1)
- neoadjuvant chemotherapy (1)
- nephrology (1)
- nephrotoxicity (1)
- neuroblastoma (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumor (NET) (1)
- neuroendocrine tumors (1)
- neuroendocrine tumors (NET) (1)
- neuroinflammation (1)
- neurology (1)
- nicotinic receptors (1)
- nitrate and thyroid carcinogenesis (1)
- non-Hodgkin's lymphoma (1)
- non-hodgkins-lymphoma (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- nuclear medicine therapy (1)
- oligorecurrence (1)
- ollimator (1)
- optimization (1)
- organic cation transporter (1)
- osteoporosis (1)
- other radiation exposure (atomic bombing/nuclear accidents) (1)
- outcomes research (1)
- overall survival (1)
- oxaliplatin (1)
- pancreas (1)
- pancreatic cancer (1)
- papillary (1)
- papillary thyroid carcinoma (PTC) (1)
- parathyroid adenoma (1)
- parathyroid carcinoma (1)
- pattern (1)
- pediatric patients (1)
- pediatric thyroid cancer after Chernobyl and Fukushima (1)
- pembrolizumab (1)
- peptide receptor (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- performance (1)
- peripheral injury (1)
- peripheral nervous system (1)
- phaeochromocytoma (1)
- phantom (1)
- phenethylguanidine (1)
- phosphatidylinositol-3-kinase (1)
- phosphorylation (1)
- photons (1)
- pig model (1)
- pleural mesothelioma (1)
- polymyalgia rheumatica (1)
- pooled (1)
- positron-emission-tomography (1)
- post-reconstruction filtering (1)
- power-station accident (1)
- preclinical imaging (1)
- prediction (1)
- preoperative localization (1)
- primary hyperparathyroidism (1)
- prognostic value (1)
- progression (1)
- prostate-specific antigen (1)
- pulmonary imaging (1)
- quality (1)
- quantification (1)
- quantitative MRI (1)
- quantitative imaging (1)
- radiation (1)
- radiation effects (1)
- radiobiology (1)
- radiochemistry (1)
- radiogenomics (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- radium (1)
- rats (1)
- recurrence (1)
- recurrent prostate cancer (1)
- refractory (1)
- renal (1)
- renal failure (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- renin-angiotensin system (1)
- repeat surgery (1)
- repeated surgery (1)
- reporting and data systems (1)
- response evaluation (1)
- responsivity (1)
- rising incidence of thyroid cancer (1)
- risk assessment (1)
- scanner (1)
- screening and overdiagnosis (1)
- second hit (1)
- second primary malignancy (1)
- secondary lung tumors (1)
- self‐gated (1)
- selpercatinib (1)
- sepsis (1)
- sigma-1 receptor-directed molecular imaging (1)
- signal to noise ratio (1)
- signaling pathway (1)
- simultaneous integrated boost (1)
- single photon emission computed tomography (SPECT) (1)
- single photon emission computed tomography: sympathetic nerve (1)
- skeletal (1)
- skin biopsy (1)
- skin hemagioma (1)
- small animal (1)
- small animal SPECT (1)
- small-animal imaging (1)
- smoldering myeloma (1)
- software (1)
- solid surrogate source (1)
- solid tumors (1)
- somatostatin (1)
- somatostatin receptors (1)
- sorbents (1)
- spin lock (1)
- spin-lock (1)
- spleen (1)
- split renal function (1)
- staging (1)
- standardization (1)
- standardization of SPECT/CT imaging (1)
- standardized reporting system (1)
- statin (1)
- stem cell therapy (1)
- stem cells (1)
- stem-cell research (1)
- stem-cell transplantation (1)
- stimulation (1)
- storage vesicle turnover (1)
- striatum (1)
- stroke (1)
- structure–activity relationships (1)
- subthalamic nucleus (1)
- super ultraviolet (1)
- surgery (1)
- surgical treatment (1)
- target (1)
- taxane (1)
- therapeutic medical radiation exposure (EBRT/ RAI) (1)
- therapeutic target (1)
- thyroid (1)
- thyroid carcinoma (TC) (1)
- thyroid carcinomas (1)
- total lesion PSMA (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- traceability of SPECT/CT imaging (1)
- tracer (1)
- trachea (1)
- transcriptome (1)
- treatment (1)
- treatment response (1)
- trial (1)
- tumor (1)
- tumor burden (1)
- tumor heterogeneity (1)
- tumor microenvironment (1)
- unilateral ureteral obstruction (1)
- urology (1)
- valsartan (1)
- various cancer diseases (1)
- vasculature (1)
- vasculitis (1)
- vemurafenib (1)
- vestibular schwannoma (1)
- wave‐CAIPI (1)
- weight drop (1)
- whole body MRI (1)
- whole-body (1)
- young females (1)
- α-Emitter (1)
- α-Particle (1)
- α-emitter (1)
- β-catenin (1)
- γ-h2ax (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (175) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (11)
- Johns Hopkins University School of Medicine (4)
- Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, Germany (1)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (1)
- Department of Nuclear Medicine, Kanazawa University (1)
- Department of Nuclear Medicine, Philipps University Marburg, Marburg, Germany (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (1)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (1)
- Johns Hopkins Medicine (1)
Background
\(^{177}\)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The compound OPS201 is the novel somatostatin antagonist showing the highest SST2 affinity. The aim of this study was to measure the in vivo biodistribution and dosimetry of \(^{177}\)Lu-OPS201 in five anesthetized Danish Landrace pigs as an appropriate substitute for humans to quantitatively assess the absorbed doses for future clinical applications.
Results
\(^{177}\)Lu-OPS201 was obtained with a specific activity ranging from 10 to 17 MBq/μg. Prior to administration, the radiochemical purity was measured as s > 99.7 % in all cases. After injection, fast clearance of the compound from the blood stream was observed. Less than 5 % of the injected activity was presented in blood 10 min after injection. A series of SPECT/CT and whole-body scans conducted until 10 days after intravenous injection showed uptake mostly in the liver, spine, and kidneys. There was no visible uptake in the spleen. Blood samples were taken to determine the time-activity curve in the blood. Time-activity curves and time-integrated activity coefficients were calculated for the organs showing visible uptake. Based on these data, the absorbed organ dose coefficients for a 70-kg patient were calculated with OLINDA/EXM. For humans after an injection of 5 GBq \(^{177}\)Lu-OPS201, the highest predicted absorbed doses are obtained for the kidneys (13.7 Gy), the osteogenic cells (3.9 Gy), the urinary bladder wall (1.8 Gy), and the liver (1.0 Gy). No metabolites of 177Lu-OPS201 were found by radio HPLC analysis. None of the absorbed doses calculated will exceed organ toxicity levels.
Conclusions
The \(^{177}\)Lu-OPS201 was well tolerated and caused no abnormal physiological or behavioral signs. In vivo distributions and absorbed doses of pigs are comparable to those observed in other publications. According to the biodistribution data in pigs, presented in this work, the expected radiation exposure in humans will be within the acceptable range.
Background
Solitary metastases to the pancreas are rare. Therefore the value of resection in curative intention remains unclear. In the literature there are several promising reports about resection of solitary metastasis to the pancreas mainly of renal origin.
Case presentation
Here we report for the first time on the surgical therapy of a 1.5 cm solitary pancreatic metastasis of an adrenocortical carcinoma. The metastasis occurred almost 6 years after resection of the primary tumor. A partial pancreatoduodenectomy was performed and postoperatively adjuvant mitotane treatment was initiated. During the follow-up of 3 years after surgery no evidence of tumor recurrence occurred.
Conclusion
Resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.
Background:
Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning.
Methods
Thirteen adolescent male patients (9–16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH.
Results
On-MPH status was associated with a highly significant change (−29.9%) of striatal DAT BP as compared to off-MPH (t = −4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04).
Conclusion
Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.
Background: Sorbents have been shown to adsorb iodinated radiocontrast media. Objective: In this study we describe a simple method to compare various sorbents in terms of capacity to adsorb radiocontrast media. Methods: Iodixanol solution was injected into columns filled with three types of sorbent at filtration velocities of increasing magnitude. Two variables of interest – contrast removal rate and matched iodine retention (MIR) – were calculated to measure the adsorption efficiency and the mass of contrast iodine adsorbed versus sorbent used, respectively. Results: The highest contrast removal and MIR for Porapak Q, CST 401 and Amberlite XAD4 were 41, 38 and 16% (p = 0.22 and 0.0005 for comparisons between Porapak Q-CST 401 and CST 401-Amberlite XAD4) and 0.060, 0.055 and 0.024, respectively (p = 0.18 and 0.0008). Extrapolation to a clinical scenario may suggest that removal of 8 ml iodixanol could be achieved by masses of sorbents of 43, 47 and 107 g, respectively. Conclusion: In this study we set a benchmark for comparing the radiocontrast-adsorbing efficiency of polymer sorbents during first-pass experiments, using a readily available methodology.
With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up. In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus, EANM believes that, beyond in vitro and preclinical evaluations, radiobiology will bring important added value to clinical studies and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radiobiologists, medical physicists, and physicians to foster research toward precision nuclear medicine.